Health Care/Hospital
GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings
YONGIN, South Korea, June 4, 2024 /PRNewswire/ -- GC Biopharma announced that it will attend 2024 Spring Symposium of the Korean American Society in Biotech and Pharmaceuticals (KASBP) onJune 7-8th at Waltham, Massachusetts as a sponsor to share keynote presentation, present Korean Scientist Awar...
2024-06-04 13:00
1504
Global Heart Hub urges people to "Think Cardiomyopathy" with new Global Campaign
GALWAY, Ireland, June 4, 2024 /PRNewswire/ -- Global Heart Hub (GHH), the international alliance of heart patient organisations, today launches its 2024 Cardiomyopathy Awareness Campaign, along with cardiomyopathy patient organisations across the globe. Cardiomyopathy is a disease of the heart m...
2024-06-04 13:00
1431
Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety
SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest results from a Phase...
2024-06-04 12:51
1511
Zespri Paves the Way to Brighter Lives Through Nurturing Healthy Eating In Children
Zespri explores the impact of fruit and vegetable consumption on children's wellbeing in world-first childhood dietary intervention study. MOUNT MAUNGANUI, New Zealand, June 4, 2024 /PRNewswire/ -- Zespri, the world's leading marketer of kiwifruit, is investing in building knowledge and healthy ...
2024-06-04 10:00
1707
Fapon Biopharma Announces a Safer Immunotherapy for Cancers
SAN DIEGO, June 3, 2024 /PRNewswire/ -- At Bio International Convention 2024, which is taking place here inSan Diego during June 3-6, Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, has announced an immunocytokine with modified IL-10M fused to anti-PD-1 ant...
2024-06-04 09:42
1027
RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88
YANTAI, China, June 4, 2024 /PRNewswire/ -- RemeGen Co., Ltd.
2024-06-04 09:38
1572
Waters Sets New Standards for High Resolution Performance and Speed with Xevo MRT Mass Spectrometer
News Summary: * Waters Xevo™ MRT Mass Spectrometer employs next-generation multi-reflecting time-of-flight technology to deliver class-leading combination of high resolution and speed without compromising analytical performance.i * Delivers up to 6x resolution at maximum speed and up to 2x ma...
2024-06-04 08:00
1454
ATTEND FDI WORLD DENTAL FEDERATION'S VIRTUAL SUMMIT SHOWCASING SUSTAINABLE PRACTICES IN DENTISTRY TO REDUCE THE PROFESSION'S ENVIRONMENTAL IMPACT
GENEVA, June 4, 2024 /PRNewswire/ -- FDI World Dental Federation (FDI) proudly
announces the upcoming second edition of its virtualSummit on Sustainability in
Dentistry
2024-06-04 06:00
1729
Optimi Health Awarded Drug Establishment Licence From Health Canada
VANCOUVER, BC, June 3, 2024 /PRNewswire/ -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a leading Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to ...
2024-06-03 23:49
1053
BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx
ADELAIDE, South Australia, June 3, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced the exclusive rights to utilize CelluTx's Recombination Based Plasmid System (RBPS) technology with BioCina's CDMO clients....
2024-06-03 23:37
2405
Datasea Agreement already provided $2.8 million Information Service for its Highly Specialized 5G-AI Communications Platform
Agreement to Have Powerful Revenue Impact and is Expected to Lead to More Lucrative Contracts BEIJING, June 3, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada company engaged in innovative business segments in high-tech intelligent acoustics and 5G-Artifici...
2024-06-03 22:00
3092
Minghui Pharmaceutical Presents Phase 1/2 Clinical Data of MHB088C (B7-H3 ADC) as Monotherapy for the Treatment of Patients with Recurrent or Metastatic Solid Tumors at the 2024 ASCO Annual Meeting
SHANGHAI, June 3, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company, announced today that the preliminary Phase 1/2 clinical data of MHB088C (B7-H3 ADC) was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in an ora...
2024-06-03 21:30
5606
Visionary Pioneering Innovation Across Four Key Frontiers
TORONTO, June 3, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries inCanada and market partners inChina, today announced the Company is pioneeri...
2024-06-03 20:30
2882
Waters Becomes First Liquid Chromatography Column Provider to Receive My Green Lab ACT Ecolabel Certification
News Summary: * Waters becomes the first vendor to obtain ACT™ Ecolabel Certification for 42 of its liquid chromatography columns, providing independent validation of the environmental impact of Waters column manufacturing, use, packaging, and disposal. * Laboratory products that earn the AC...
2024-06-03 20:00
1710
HistoIndex to Showcase Groundbreaking AI-powered Stain-free Digital Pathology Advances with 8 Accepted Abstracts at EASL Congress 2024
* Company to deliver two oral and six poster presentations, including one TOP poster and one selected for poster tour, further reinforcing its leadership position in MASH digital pathology. * HistoIndex's AI-driven solutions provide unprecedented insights into the direct prediction of patient...
2024-06-03 20:00
1974
Psylo Announces First Close on $8 Million Series Seed Financing to Advance Next-Generation Neuroplastogens at BIO Conference in San Diego
Innovative biotech company pioneers PSYLO-100X, a non-hallucinogenic neuroplastogen with promising therapeutic potential SAN DIEGO, June 3, 2024 /PRNewswire/ -- Psylo, a leading biotechnology company focused on the development of next-generation neuroplastogens, today announced at the BIO Confer...
2024-06-03 20:00
1527
MGI Tech's DNBSEQ-E25 and G99 Platforms Set Record for Sequencing Applications on Mount Everest
SHENZHEN, China, June 2, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, recently set a new record for sequencing applications by successfully running sample testing on its cutting-edge DNBSEQ-E25 ...
2024-06-03 11:35
1531
Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual Meeting.
NANJING, China, June 2, 2024 /PRNewswire/ -- The annual meeting of the American Society of Clinical Oncology (ASCO) commenced onMay 31st, Showcasing groundbreaking cancer research from around the world. According to official information, over 7,000 abstracts were submitted this year. After rigoro...
2024-06-03 10:57
1834
Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting
* Results from the phase I part of JSKN003-102 was reported at this ASCO Annual Meeting. * JSKN003 exhibited a favorable tolerability and manageable safety profile in heavily pretreated patients with advanced/metastatic solid tumors and demonstrated encouraging antitumor activity during dose ...
2024-06-03 10:17
1756
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and ot...
2024-06-03 09:44
2250
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7722
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7116